• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Campbell Shane Alden

    5/14/25 4:08:34 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Campbell Shane Alden

    (Last) (First) (Middle)
    530 HERMAN O. WEST DRIVE

    (Street)
    EXTON PA 19341

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    WEST PHARMACEUTICAL SERVICES INC [ WST ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Proprietary Segment
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Rst. Stock Unit (1) (1) Common Stock 1,891 $0 D
    Rst. Stock Unit (1) (1) Common Stock 1,182 $0 D
    Stock Options (Right to Buy) 05/12/2026(1) 05/12/2035 Stock Options (Right to Buy) 2,852 $219.46 D
    Explanation of Responses:
    1. This award vests in four equal annual installments beginning on May 12, 2026.
    /s/ Louis Lalli, as an agent for Shane Alden Campbell 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    6/24/2025$245.00Equal Weight
    Barclays
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    2/7/2024$323.00 → $536.00Hold → Buy
    Jefferies
    6/16/2023$390.00 → $405.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on West Pharm with a new price target

    Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

    3/18/25 7:58:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharm upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

    2/14/25 7:09:40 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcmahon Robert W.

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    8/12/25 7:21:15 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP & Chief Financial Officer Mcmahon Robert W.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    8/12/25 7:19:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    New insider Poussot Rodolphe Jean claimed ownership of 253 shares (SEC Form 3)

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    8/1/25 4:14:13 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance

    - Conference Call Scheduled for 8 a.m. EDT Today - EXTON, Pa., July 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend. Second-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $766.5 million increased 9.2%; organic net sales growth was 6.8%.Diluted EPS of $1.82, compared to $1.51 in the same period last year.Adjusted-diluted EPS of $1.84, compared to $1.52 in the same period last year.Updates full-year 2025 net sales guidance range to $3.

    7/24/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Second-Quarter 2025 Conference Call

    EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone participa

    7/8/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    SEC Filings

    View All

    SEC Form 10-Q filed by West Pharmaceutical Services Inc.

    10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    7/24/25 4:22:04 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    7/24/25 7:17:23 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    7/21/25 4:17:14 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Financials

    Live finance-specific insights

    View All

    West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance

    - Conference Call Scheduled for 8 a.m. EDT Today - EXTON, Pa., July 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend. Second-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $766.5 million increased 9.2%; organic net sales growth was 6.8%.Diluted EPS of $1.82, compared to $1.51 in the same period last year.Adjusted-diluted EPS of $1.84, compared to $1.52 in the same period last year.Updates full-year 2025 net sales guidance range to $3.

    7/24/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Second-Quarter 2025 Conference Call

    EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone participa

    7/8/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Announces Leadership Changes

    Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

    4/24/25 6:10:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    5/12/22 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/14/23 12:37:59 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/10/22 8:47:14 AM ET
    $WST
    Medical/Dental Instruments
    Health Care